Skip to main content
SpringerLink
Log in

Overview of Inpatient Management of Hypertriglyceridemia Associated Acute Pancreatitis in Patients with Diabetes Mellitus

  • Chapter
  • First Online:
Diabetes Management in Hospitalized Patients

Part of the book series: Contemporary Endocrinology ((COE))

  • 252 Accesses

Abstract

Dyslipidemia associated with diabetes mellitus (DM) has been identified as a risk factor for acute pancreatitis. Hypertriglyceridemia is often seen in patients with diabetes mellitus and is a known cause of acute pancreatitis. In acute pancreatitis caused by hypertriglyceridemia, insulin has been found to be the most effective therapy due to its ability for dose adjustment and its anti-inflammatory properties. It has been a topic of discussion whether to use low rates of intravenous (IV) insulin and dextrose fluids versus higher rates for hypertriglyceridemia-induced acute pancreatitis. We will also discuss evidence on acute pancreatitis risks associated with certain DM medications. This chapter provides an overview of the inpatient care of those with diabetes mellitus and acute pancreatitis.

We thank Vishnu Priya Pulipati for their expert suggestions and involvement in the critical review of the chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Tsalamandris S, Antonopoulos AS, Oikonomou E, Papamikroulis GA, Vogiatzi G, Papaioannou S, et al. The role of inflammation in diabetes: current concepts and future perspectives. Eur Cardiol. 2019;14(1):50–9.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Feuerer M, Shen Y, Littman DR, Benoist C, Mathis D. How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. Immunity. 2009;31(4):654–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Thomas HE, Darwiche R, Corbett JA, Kay TWH. Interleukin-1 plus γ-interferon-induced pancreatic β-cell dysfunction is mediated by β-cell nitric oxide production. Diabetes. 2002;51(2):311–6.

    Article  CAS  PubMed  Google Scholar 

  4. Pradhan AD. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327.

    Article  CAS  PubMed  Google Scholar 

  5. Thorand B, Löwel H, Schneider A, Kolb H, Meisinger C, Fröhlich M, et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med. 2003;163(1):93.

    Article  CAS  PubMed  Google Scholar 

  6. Antonopoulos AS, Tousoulis D. The molecular mechanisms of obesity paradox. Cardiovasc Res. 2017;113(9):1074–86.

    Article  CAS  PubMed  Google Scholar 

  7. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132(6):2169–80.

    Article  CAS  PubMed  Google Scholar 

  8. Kanda H. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest. 2006;116(6):1494–505.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Antonopoulos AS, Margaritis M, Coutinho P, Shirodaria C, Psarros C, Herdman L, et al. Adiponectin as a link between type 2 diabetes and vascular NADPH oxidase activity in the human Arterial Wall: the regulatory role of perivascular adipose tissue. Diabetes. 2015;64(6):2207–19.

    Article  CAS  PubMed  Google Scholar 

  10. Antoniades C, Antonopoulos AS, Tousoulis D, Stefanadis C. Adiponectin: from obesity to cardiovascular disease. Obes Rev. 2009;10(3):269–79.

    Article  CAS  PubMed  Google Scholar 

  11. Nikolajczyk BS, Jagannathan-Bogdan M, Shin H, Gyurko R. State of the union between metabolism and the immune system in type 2 diabetes. Genes Immun. 2011;12(4):239–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ehses JA, Perren A, Eppler E, Ribaux P, Pospisilik JA, Maor-Cahn R, et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes. 2007;56(9):2356–70.

    Article  CAS  PubMed  Google Scholar 

  13. Pang Y, Kartsonaki C, Turnbull I, Guo Y, Yang L, Bian Z, et al. Metabolic and lifestyle risk factors for acute pancreatitis in Chinese adults: a prospective cohort study of 0.5 million people. PLoS Med. 2018;15(8):e1002618.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Aune D, Mahamat-Saleh Y, Norat T, Riboli E. Diabetes mellitus and the risk of pancreatitis: a systematic review and meta-analysis of cohort studies. Pancreatology. 2020;20(4):602–7.

    Article  PubMed  Google Scholar 

  15. Girman CJ, Kou TD, Cai B, Alexander CM, O’Neill EA, Williams-Herman DE, et al. Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obes Metab. 2010;12(9):766–71.

    Article  CAS  PubMed  Google Scholar 

  16. Valdivielso P, Ramírez-Bueno A, Ewald N. Current knowledge of hypertriglyceridemic pancreatitis. Eur J Intern Med. 2014;25(8):689–94.

    Article  CAS  PubMed  Google Scholar 

  17. Boxhoorn L, Voermans RP, Bouwense SA, Bruno MJ, Verdonk RC, Boermeester MA, et al. Acute pancreatitis. Lancet Lond Engl. 2020;396(10252):726–34.

    Article  Google Scholar 

  18. Peery AF, Crockett SD, Barritt AS, Dellon ES, Eluri S, Gangarosa LM, et al. Burden of gastrointestinal, liver, and pancreatic diseases in the United States. Gastroenterology. 2015;149(7):1731–1741.e3.

    Article  PubMed  Google Scholar 

  19. Koutroumpakis E, Slivka A, Furlan A, Dasyam AK, Dudekula A, Greer JB, et al. Management and outcomes of acute pancreatitis patients over the last decade: a US tertiary-center experience. Pancreatol Off J Int Assoc Pancreatol IAP Al. 2017;17(1):32–40.

    Google Scholar 

  20. Forsmark CE, Baillie J. AGA Institute clinical practice and economics committee, AGA Institute governing board. AGA Institute technical review on acute pancreatitis. Gastroenterology. 2007;132(5):2022–44.

    Article  CAS  PubMed  Google Scholar 

  21. Tsuang W, Navaneethan U, Ruiz L, Palascak JB, Gelrud A. Hypertriglyceridemic pancreatitis: presentation and management. Am J Gastroenterol. 2009;104(4):984–91.

    Article  CAS  PubMed  Google Scholar 

  22. Scherer J, Singh VP, Pitchumoni CS, Yadav D. Issues in hypertriglyceridemic pancreatitis: an update. J Clin Gastroenterol. 2014;48(3):195–203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Garg R, Rustagi T. Management of hypertriglyceridemia induced acute pancreatitis. Biomed Res Int. 2018;2018:1–12.

    Article  Google Scholar 

  24. Jacobs MJ, Kleisli T, Pio JR, Malik S, L’Italien GJ, Chen RS, et al. Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract. 2005;70(3):263–9.

    Article  PubMed  Google Scholar 

  25. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med. 2001;135(6):447–59.

    Article  CAS  PubMed  Google Scholar 

  26. Eckel RH, Yost TJ, Jensen DR. Alterations in lipoprotein lipase in insulin resistance. Int J Obes Relat Metab Disord J Int Assoc Study Obes. 1995;19(Suppl 1):S16–21.

    Google Scholar 

  27. Rawla P, Sunkara T, Thandra KC, Gaduputi V. Hypertriglyceridemia-induced pancreatitis: updated review of current treatment and preventive strategies. Clin J Gastroenterol. 2018;11(6):441–8.

    Article  PubMed  Google Scholar 

  28. Coskun A, Erkan N, Yakan S, Yildirim M, Carti E, Ucar D, et al. Treatment of hypertriglyceridemia-induced acute pancreatitis with insulin. Przeglad Gastroenterol. 2015;10(1):18–22.

    CAS  Google Scholar 

  29. Li J, Chen TR, Gong HL, Wan MH, Chen GY, Tang WF. Intensive insulin therapy in severe acute pancreatitis: a meta-analysis and systematic review. West Indian Med J. 2012;61(6):574–9.

    CAS  PubMed  Google Scholar 

  30. Thuzar M, Shenoy VV, Malabu UH, Schrale R, Sangla KS. Extreme hypertriglyceridemia managed with insulin. J Clin Lipidol. 2014;8(6):630–4.

    Article  PubMed  Google Scholar 

  31. Kuchay MS, Farooqui KJ, Bano T, Khandelwal M, Gill H, Mithal A. Heparin and insulin in the management of hypertriglyceridemia-associated pancreatitis: case series and literature review. Arch Endocrinol Metab. 2017;61(2):198–201.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Samarasinghe S, Avari P, Meeran K, Cegla J. Management of hypertriglyceridaemic pancreatitis in the acute setting and review of literature. BMJ Case Rep. 2018;11(1):e227594.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Twilla JD, Mancell J. Hypertriglyceridemia-induced acute pancreatitis treated with insulin and heparin. Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm. 2012;69(3):213–6.

    Article  CAS  Google Scholar 

  34. Jin M, Peng JM, Zhu HD, Zhang HM, Lu B, Li Y, et al. Continuous intravenous infusion of insulin and heparin vs plasma exchange in hypertriglyceridemia-induced acute pancreatitis. J Dig Dis. 2018;19(12):766–72.

    Article  CAS  PubMed  Google Scholar 

  35. Xie C, Stevens DC, Sturm T. Safe and effective triglyceride-lowering therapy for hypertriglyceridemia associated pancreatitis: insulin mono-therapy in a non-diabetic patient. S D Med J S D State Med Assoc. 2018;71(1):26–8.

    Google Scholar 

  36. Badiu C. Williams textbook of endocrinology. Acta Endocrinol Buchar. 2019;15(3):416. (Semenkovich C, Golderg, IJ. Disorders of Lipid Metabolism In: Badiu, C. Williams textbook of endocrinology. Acta Endocrinol Buchar; 2019. p. 1581–1620).

    Google Scholar 

  37. Pulipati VP, Amblee A, Yap SET, Shaka H, Tahsin B, Fogelfeld L. Hypertriglyceridemia-associated acute pancreatitis: response to continuous insulin infusion. Rakonczay Z, editor. PLoS One. 2021;16(11):e0260495.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Yang AL, McNabb-Baltar J. Hypertriglyceridemia and acute pancreatitis. Pancreatology. 2020;20(5):795–800.

    Article  CAS  PubMed  Google Scholar 

  39. Kelly JL. Continuous insulin infusion: when, where, and how? Diabetes Spectr Publ Am Diabetes Assoc. 2014;27(3):218–23.

    Article  Google Scholar 

  40. American Diabetes Association Professional Practice Committee. Diabetes care in the hospital: standards of medical Care in Diabetes—2022. Diabetes Care. 2022;45(Supplement_1):S244–53.

    Article  Google Scholar 

  41. Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the writing Committee of the American Society for apheresis: the eighth special issue. J Clin Apheresis. 2019;34(3):171–354.

    Article  PubMed  Google Scholar 

  42. Chen JH, Yeh JH, Lai HW, Liao CS. Therapeutic plasma exchange in patients with hyperlipidemic pancreatitis. World J Gastroenterol. 2004;10(15):2272.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Gubensek J, Buturovic-Ponikvar J, Romozi K, Ponikvar R. Factors affecting outcome in acute hypertriglyceridemic pancreatitis treated with plasma exchange: an observational cohort study. Rakonczay Z, editor. PLoS One. 2014;9(7):e102748.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Karalis DG. A review of clinical practice guidelines for the management of hypertriglyceridemia: a focus on high dose Omega-3 fatty acids. Adv Ther. 2017;34(2):300–23.

    Article  CAS  PubMed  Google Scholar 

  45. Wu BU, Batech M, Dong EY, Duan L, Yadav D, Chen W. Influence of ambulatory triglyceride levels on risk of recurrence in patients with hypertriglyceridemic pancreatitis. Dig Dis Sci. 2019;64(3):890–7.

    Article  CAS  PubMed  Google Scholar 

  46. Christian JB, Arondekar B, Buysman EK, Jacobson TA, Snipes RG, Horwitz RI. Determining triglyceride reductions needed for clinical impact in severe hypertriglyceridemia. Am J Med. 2014;127(1):36–44.e1.

    Article  CAS  PubMed  Google Scholar 

  47. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1—full report. J Clin Lipidol. 2015;9(2):129–69.

    Article  PubMed  Google Scholar 

  48. Goldberg RB, Chait A. A comprehensive update on the chylomicronemia syndrome. Front Endocrinol. 2020;11:593931.

    Article  Google Scholar 

  49. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–97.

    Article  Google Scholar 

  50. Pulipati VP, Brinton EA, Hatipoglu B. Management of mild-to-moderate hypertriglyceridemia. Endocr Pract. 2022;28(11):1187–95.

    Article  PubMed  Google Scholar 

  51. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 2001;104(25):3046–51.

    Article  CAS  PubMed  Google Scholar 

  52. Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51(7):724–30.

    Article  CAS  PubMed  Google Scholar 

  53. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123(20):2292–333.

    Article  PubMed  Google Scholar 

  54. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis Off J Natl Kidney Found. 2003;41(4 Suppl 3):I–IV, S1–91.

    Google Scholar 

  55. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol. 2007;99(6A):3C–18C.

    Article  CAS  PubMed  Google Scholar 

  56. Shearer GC, Savinova OV, Harris WS. Fish oil—how does it reduce plasma triglycerides? Biochim Biophys Acta BBA Mol Cell Biol Lipids. 2012;1821(5):843–51.

    CAS  Google Scholar 

  57. Oscarsson J, Hurt-Camejo E. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. Lipids Health Dis. 2017;16(1):149.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with Icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22.

    Article  CAS  PubMed  Google Scholar 

  59. HPS2-THRIVE Collaborative Group, Haynes R, Jiang L, Hopewell JC, Li J, Chen F, et al. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34(17):1279–91.

    Article  PubMed Central  Google Scholar 

  60. The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–67.

    Article  Google Scholar 

  61. The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with Laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–12.

    Article  Google Scholar 

  62. Huffman GB. Aspirin therapy to reduce cutaneous reactions to niacin. Am Fam Physician. 1998;57(8):1933.

    Google Scholar 

  63. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1–based therapies. Gastroenterology. 2011;141(1):150–6.

    Article  CAS  PubMed  Google Scholar 

  64. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.

    Article  CAS  PubMed  Google Scholar 

  65. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–51.

    Article  CAS  PubMed  Google Scholar 

  66. Cao C, Yang S, Zhou Z. GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials. Endocrine. 2020;68(3):518–25.

    Article  CAS  PubMed  Google Scholar 

  67. Smits MM, Van Raalte DH. Safety of semaglutide. Front Endocrinol. 2021;12:645563.

    Article  Google Scholar 

  68. Lando HM, Alattar M, Dua AP. Elevated amylase and lipase levels in patients using glucagonlike Peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting. Endocr Pract. 2012;18(4):472–7.

    Article  PubMed  Google Scholar 

  69. Tokuyama H, Kawamura H, Fujimoto M, Kobayashi K, Nieda M, Okazawa T, et al. A low-grade increase of serum pancreatic exocrine enzyme levels by dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes. Diabetes Res Clin Pract. 2013;100(3):e66–9.

    Article  CAS  PubMed  Google Scholar 

  70. Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318(15):1460.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Steinberg WM, Rosenstock J, Wadden TA, Donsmark M, Jensen CB, DeVries JH. Impact of Liraglutide on amylase, lipase, and acute pancreatitis in participants with overweight/obesity and normoglycemia, prediabetes, or type 2 diabetes: secondary analyses of pooled data from the SCALE clinical development program. Diabetes Care. 2017;40(7):839–48.

    Article  CAS  PubMed  Google Scholar 

  72. Steinberg WM, Buse JB, Ghorbani MLM, Ørsted DD, Nauck MA, The LEADER Steering Committee, et al. Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with liraglutide: results from the LEADER randomized trial. Diabetes Care. 2017;40(7):966–72.

    Article  CAS  PubMed  Google Scholar 

  73. Smits MM, Tonneijck L, Muskiet MHA, Kramer MHH, Pieters-van Den Bos IC, Vendrik KEW, et al. Pancreatic effects of liraglutide or sitagliptin in overweight patients with type 2 diabetes: a 12-week randomized, placebo-controlled trial. Diabetes Care. 2017;40(3):301–8.

    Article  CAS  PubMed  Google Scholar 

  74. Egan AG, Blind E, Dunder K, De Graeff PA, Hummer BT, Bourcier T, et al. Pancreatic safety of incretin-based drugs—FDA and EMA assessment. N Engl J Med. 2014;370(9):794–7.

    Article  CAS  PubMed  Google Scholar 

  75. Kalra S, Das AK, Sahay RK, Baruah MP, Tiwaskar M, Das S, et al. Consensus recommendations on GLP-1 RA use in the management of type 2 diabetes mellitus: south Asian task force. Diabetes Ther. 2019;10(5):1645–717.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet Lond Engl. 2006;368(9548):1696–705.

    Article  CAS  Google Scholar 

  77. Zhang X, Wang M, Wang X, Zhu Z, Zhang W, Zhou Z, et al. Comparison of new glucose-lowering drugs on the risk of pancreatitis in type 2 diabetes: a network meta-analysis. Endocr Pract. 2022;28(3):333–41.

    Article  PubMed  Google Scholar 

  78. Tkáč I, Raz I. Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care. 2017;40(2):284–6.

    Article  PubMed  Google Scholar 

  79. Wang T, Wang F, Gou Z, Tang H, Li C, Shi L, et al. Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1 324 515 patients from observational studies. Diabetes Obes Metab. 2015;17(1):32–41.

    Article  CAS  PubMed  Google Scholar 

  80. Giorda CB, Sacerdote C, Nada E, Marafetti L, Baldi I, Gnavi R. Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies. Endocrine. 2015;48(2):461–71.

    Article  CAS  PubMed  Google Scholar 

  81. Blonde L, Umpierrez GE, Reddy SS, McGill JB, Berga SL, Bush M, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: developing a diabetes mellitus comprehensive care plan—2022 update. Endocr Pract. 2022;28(10):923–1049.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Kodali AM, Pantalone KM, Tsushima Y. RF28 | PSUN182 risk of pancreatitis after Glp-1 receptor agonist in individuals with known history of pancreatitis. J Endocr Soc. 2022;6(Supplement_1):A426–7.

    Article  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Department of Medicine, North Shore University and Long Island Jewish Medical Center, Northwell Health, Manhasset, NY, USA

    Fuad Benyaminov & Avani Sinha

  2. Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA

    Fuad Benyaminov & Avani Sinha

Authors
  1. Fuad Benyaminov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Avani Sinha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fuad Benyaminov .

Editor information

Editors and Affiliations

  1. Division of Endocrinology, Long Island Jewish Medical Center, Northwell Health, New Hyde Park, NY, USA

    Rifka C. Schulman-Rosenbaum

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Benyaminov, F., Sinha, A. (2023). Overview of Inpatient Management of Hypertriglyceridemia Associated Acute Pancreatitis in Patients with Diabetes Mellitus. In: Schulman-Rosenbaum, R.C. (eds) Diabetes Management in Hospitalized Patients. Contemporary Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-031-44648-1_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-44648-1_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-44647-4

  • Online ISBN: 978-3-031-44648-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation